Colitis Clinical Trial - Treatment of Microscopic Colitis

Status Terminated

Clinical Trial Summary

The study compares the effect of Budesonide, Bismuth and fiber in patients with microscopic colitis

Clinical Trial Description

This randomized, controlled, open study compares the effects of 8 weeks' treatment with Budesonide, Bismuth and fiber on symptoms and histological findings in patients with microscopic colitis (both collagenous colitis and lymphocytic colitis). ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00184171
Study type	Interventional
Source	Norwegian University of Science and Technology
Contact
Status	Terminated
Phase	N/A
Start date	November 2001
Completion date	October 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00272818` - Study to Identify Non-Invasive Markers of Gastrointestinal Allergy
Completed	`NCT01369355` - A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)	Phase 3
Completed	`NCT02709213` - Determination of the Aetiologies of Acute Colitis and Early Identification of Patients Requiring Diagnostic Colonoscopy
Completed	`NCT00533078` - Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies	Phase 2
Recruiting	`NCT05333978` - Optoacoustic Detection of Inflammation Using MSOT Device	N/A
Recruiting	`NCT02768038` - Intestinal Microbiome and Chronic Inflammatory Bowel Disease
Recruiting	`NCT04272307` - MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: a Multi-omics Pilot Approach.
Completed	`NCT05514561` - FIT and Fecal Calprotectin in Patients With Chronic Lower GI Symptoms
Completed	`NCT00072943` - A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease	Phase 2
Recruiting	`NCT02687724` - Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis	Phase 4
Completed	`NCT02647866` - Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis	Phase 2
Completed	`NCT01326013` - A Two-Arm, Multi-Centre Clinical Evaluation of the xTAG Gastrointestinal Pathogen Panel	Phase 2
Not yet recruiting	`NCT05726396` - A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis	Phase 2
Completed	`NCT05414552` - ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment
Recruiting	`NCT04407247` - Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma	Phase 1/Phase 2
Completed	`NCT01369329` - A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)	Phase 3
Completed	`NCT01369342` - A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)	Phase 3
Terminated	`NCT00936585` - NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease	N/A
Completed	`NCT06074874` - Intestinal Biomarker Analysis After ECP for ICI Colitis
Recruiting	`NCT06206707` - FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis	N/A